PHARMAIDS PHARMACEUTICALS LTD.

Operates a pharmaceutical business with a drug discovery services arm, where a Vice President of Discovery Services leads the work. Through its material subsidiary Adita Bio Sys Private Limited, the company runs a laboratory accredited by the American Association for Laboratory Accreditation (A2LA) to test medical devices in the biological field under ISO/IEC 17025:2017 and US FDA Good Laboratory Practice Regulations per 21 CFR Part 58, serving medical device clients needing regulatory-grade testing. A step-down subsidiary, Spring Labs, also contributed to consolidated revenue, while step-down subsidiary Siri Labvivo Diet Private Limited was sold in March 2026 for Rs. 3 lakh. The standalone pharmaceutical entity recorded revenue of Rs. 1,060.25 lakh in FY26, up sharply from Rs. 234.09 lakh in FY25, while consolidated revenue was Rs. 2,788.24 lakh (up 43% year-on-year), with most consolidated revenue coming from the subsidiaries. The company is loss-making at both standalone and consolidated levels, with FY26 consolidated net loss of Rs. 1,157.19 lakh and operating cash outflows of Rs. 405.72 lakh. Materials consumed are the single largest cost at 52.9% of revenue, followed by employee costs at 48.0%, and the board approved a Rs. 75 lakh corporate guarantee for Adita Bio Sys under the ECLGS 5.0 scheme.